Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck will acquire oncolytic virus firm

by Ryan Cross
February 26, 2018 | A version of this story appeared in Volume 96, Issue 9

Merck & Co. will pay about $400 million to acquire the Australian biotech firm Viralytics, which is testing an oncolytic virus, part of a small but growing class of cancer therapies. The virus, which infects and kills cancer cells, will be used alongside Merck’s immunotherapy Keytruda in an attempt to expand the number of cancers and people for which Keytruda is effective.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.